GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Medical System Holdings Ltd (OTCPK:CHSYF) » Definitions » 3-Year Revenue Growth Rate

China Medical System Holdings (China Medical System Holdings) 3-Year Revenue Growth Rate : 2.40% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is China Medical System Holdings 3-Year Revenue Growth Rate?

China Medical System Holdings's Revenue per Share for the six months ended in Dec. 2023 was $0.19.

During the past 12 months, China Medical System Holdings's average Revenue per Share Growth Rate was -14.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 2.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 9.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of China Medical System Holdings was 32.40% per year. The lowest was -52.80% per year. And the median was 15.20% per year.


Competitive Comparison of China Medical System Holdings's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Medical System Holdings's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where China Medical System Holdings's 3-Year Revenue Growth Rate falls into.



China Medical System Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


China Medical System Holdings  (OTCPK:CHSYF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


China Medical System Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of China Medical System Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


China Medical System Holdings (China Medical System Holdings) Business Description

Traded in Other Exchanges
Address
510 King’s Road, Unit 2106, 21st Floor, North Point, Island Place Tower, Hong Kong, HKG
China Medical System Holdings Ltd is active in the healthcare segment. It is one of the leading China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil; Salofalk; Combizym; Ganfule Capsules; Xidakang; Hirudoid; and others. Geographically, it derives revenue from China.

China Medical System Holdings (China Medical System Holdings) Headlines